Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2021; 27(15): 1595-1615
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1595
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1595
Abelson interactor 1 splice isoform-L plays an anti-oncogenic role in colorectal carcinoma through interactions with WAVE2 and full-length Abelson interactor 1
Kun Li, Mei Li, Ting-Ru Lin, Department of Central Laboratory and Institute of Clinical Molecular Biology, Peking University People’s Hospital, Beijing 100044, China
Kun Li, Yu Zhang, Jing-Yi Chen, Ting-Ru Lin, Department of Gastroenterology, Peking University People’s Hospital, Peking University, Beijing 100044, China
Yi-Fan Peng, Gastrointestinal Cancer Center, Unit III, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China
Jing-Zhu Guo, Department of Pediatrics, Peking University People’s Hospital, Beijing 100044, China
Yu Zhang, Jing-Yi Chen, Wei-Dong Yu, Department of Central Laboratory and Institute of Clinical Molecular Biology, Peking University People's Hospital, Beijing 100044, China
Xin Yu, Department of Hepatobiliary Surgery, Peking University People’s Hospital, Beijing 100044, China
Author contributions: Li K, Peng YF, and Guo JZ contributed equally to this work and performed the majority of experiments; Li M, Zhang Y, Chen JY, Lin TR, and Yu X performed minor experiments, provided vital reagents, and were also involved in revising the manuscript; Peng YF and Yu WD designed the study, wrote the manuscript, and provided financial support; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China , No. 30872923 and No. 81672853 ; and Peking University People’s Hospital Scientific Research Development Found , No. RDH2020-11 .
Institutional review board statement: The study was reviewed and approved by the Peking University People’s Hospital Institutional Review Board (No. 2020-11).
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wei-Dong Yu, PhD, Professor, Department of Central Laboratory and Institute of Clinical Molecular Biology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. weidongyu@bjmu.edu.cn
Received: January 21, 2021
Peer-review started: January 21, 2021
First decision: February 9, 2021
Revised: February 17, 2021
Accepted: March 13, 2021
Article in press: March 13, 2021
Published online: April 21, 2021
Peer-review started: January 21, 2021
First decision: February 9, 2021
Revised: February 17, 2021
Accepted: March 13, 2021
Article in press: March 13, 2021
Published online: April 21, 2021
Core Tip
Core Tip: The purpose of this study was to investigate the role and mechanism of Abelson interactor 1 splice isoform-L (ABI1-SiL) in the metastatic behavior of colorectal carcinoma cells. Our results showed that ABI1-SiL played a key role in cell surface area, adhesion, and migration, but not in proliferation and apoptosis in SW480 cells. ABI1-SiL may have anti-oncogenic roles by competitively binding to WAVE2, and directly interacting with phosphorylated and non-phosphorylated ABI1-p65, functioning as a dominant-negative molecule towards ABI1-p65.